The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 20 December 2005, www.theannals.com, DOI 10.1345/aph.1G263.
 The Annals of Pharmacotherapy: Vol. 40, No. 1, pp. 74-82. DOI 10.1345/aph.1G263
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hughes, C. A
Right arrow Articles by Shafran, S. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hughes, C. A
Right arrow Articles by Shafran, S. D

GASTROENTEROLOGY

Chronic Hepatitis C Virus Management: 2000–2005 Update

Christine A Hughes, PharmD

Associate Professor, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta; Clinical Pharmacist, HIV, Capital Health Region, Edmonton, AB, Canada

Stephen D Shafran, MD FRCPC

Professor, Division of Infectious Diseases, Department of Medicine, University of Alberta

Reprints: Dr. Hughes, Faculty of Pharmacy and Pharmaceutical Sciences, 3126 Dentistry/Pharmacy Centre, University of Alberta, Edmonton T6G 2N8, AB, Canada, fax 780/492-1217, christine.hughes{at}ualberta.ca

OBJECTIVE: To review recent advances that have significantly changed the management of chronic hepatitis C virus (HCV) infection.

DATA SOURCES: A MEDLINE search (2000–July 2005) was conducted using key words such as hepatitis C, interferon, pegylated interferon, and therapy.

STUDY SELECTION AND DATA EXTRACTION: All articles pertaining to treatment of chronic HCV infection were identified. Studies evaluating HCV treatment in treatment-naive patients were considered for this review.

DATA SYNTHESIS: Over the past several years, response to treatment for chronic HCV infection has significantly improved with the use of pegylated interferon and ribavirin therapy. Treatment response is influenced by HCV genotype and viral load, as well as patient-related factors, including adherence.

CONCLUSIONS: Treatment of chronic HCV infection has improved, with overall response rates of approximately 55%. Identification and management of common adverse effects is important in maximizing adherence and response to therapy. Studies are needed to further delineate the optimum treatment of chronic HCV infection in specific patient populations.

Key Words: antiviral therapy, hepatitis C, interferon, pegylated interferon, ribavirin

Published Online, December 20, 2005. www.theannals.com, DOI 10.1345/aph.1G263


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
H. C. Highbarger, Z. Hu, S. Kottilil, J. A. Metcalf, M. A. Polis, M. B. Vasudevachari, H. C. Lane, and R. L. Dewar
Comparison of the Abbott 7000 and Bayer 340 Systems for Measurement of Hepatitis C Virus Load
J. Clin. Microbiol., September 1, 2007; 45(9): 2808 - 2812.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.